Sol-Gel Stock Soars Over 150% - Will Upcoming Q4 Clinical Data Support Continued Growth?
Stock Performance: Sol-Gel Technologies Ltd. (SLGL) reached a 52-week high of $18.66, indicating increased investor confidence, with expectations for continued upward momentum as clinical trial milestones approach.
Drug Development: The company has two FDA-approved products and is advancing SGT-610 for Gorlin syndrome and SGT-210 for Darier disease, both targeting rare skin conditions with significant market potential.
Clinical Trials: SGT-610 is in phase III trials with results expected in Q4 2026, while SGT-210 is in phase 1b trials with results anticipated in Q4 2025, potentially leading to substantial sales if approved.
Financial Position: As of June 30, 2025, Sol-Gel had $24.2 million in cash, sufficient to fund operations until early 2027, and the stock has seen a significant increase of over 150% since May 2025.
Trade with 70% Backtested Accuracy
Analyst Views on SLGL
About SLGL
About the author
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
What’s Causing the Decline of Small Cap Sol-Gel Tech Stock Today?
Clinical Study Update: Sol-Gel Technologies announced that the Phase 1b study of SGT-210 for Darier disease did not show efficacy compared to the vehicle, leading to a decision not to advance further in this indication. The company plans to conduct small feasibility studies in other areas of unmet medical need.
Focus on Other Programs: The Executive Chairman, Mori Arkin, emphasized the company's commitment to completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparing for a potential Phase 3 program in high-frequency basal cell carcinoma, contingent on the success of the Gorlin trial.
Stock Performance Analysis: Sol-Gel Technologies (SLGL) is currently showing strong technical indicators, trading above key moving averages, with a bullish trend supported by positive momentum in the MACD and a neutral RSI.
Recent Stock Movement: SLGL stock experienced a decline of 6.81% to $39.26, while over the past year, it has gained 735.02%, indicating a strong upward trajectory but caution is advised as it approaches resistance levels.
